Lung-targeted (inhaled) delivery of 80 μg and systemic (oral) delivery of 240 μg of DMF, administered daily for 3–6 weeks post-injury, were compared in an aging murine model of bleomycin-induced non-resolving lung fibrosis; notably, only inhaled DMF restored lung Nrf2 levels, reduced lung oxidative stress, and promoted the fibrosis resolution. Here, NFE2L2 is linked to pulmonary fibrosis.